BioPharma Resources

Drug Trial Radar · NCT02817451

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants

Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected Infants in Republic of South Africa

Last checked: Nov 19, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

53

Actual

Start

Jul 14, 2016

Primary completion

Feb 22, 2019

Study completion Feb 22, 2019

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jun 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 5 weeks, up to 8 weeks
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to assess and confirm the adequate immunogenicity and safety profile of the Sanofi Pasteur's DTaP-Hep B-IPV-PRP-T fully liquid combined hexavalent vaccine administered in HIV-exposed uninfected infants and in HIV-exposed infected infants. The primary objectives of the study are: * To evaluate the immunogenicity of the study vaccine 1 month after the 3-dose primary series in HIV-exposed infected and in HIV-exposed uninfected infants. * To describe the persistence of all antibodies before receipt of the booster dose in HIV-exposed infected and in HIV-exposed uninfected infants. * To evaluate the immunogenicity of the study vaccine 1 month after the booster dose in HIV-exposed infected and in HIV-exposed uninfected infants. The secondary objectives of the study are: * To describe the safety profile after each and all doses of the study vaccine administered as a 3-dose infant primary series in HIV-exposed infected and in HIV-exposed uninfected infants. * To describe the safety profile of the study vaccine administered as a booster in HIV-exposed infected and in HIV-exposed uninfected infants.

Conditions

  • Diphtheria
  • Tetanus
  • Pertussis
  • Hepatitis B
  • Polio
  • Human Immunodeficiency Virus Infection

Interventions

  • Hexaxim®: DTaP-IPV-HB-PRP-T Combined VaccineBiological

    0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months

  • Hexaxim®: DTaP-IPV-HB-PRP-T Combined VaccineBiological

    0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Anti-Pertussis Toxoid (PT) and Anti-Filamentous Hemagglutinin (FHA) Antibody (Ab) Concentrations >= Lower Limit of Quantification (LLOQ) and >=4*LLOQ at BaselineTime frame: Day 0 (baseline)
  2. Geometric Means of Anti-Pertussis Toxoid and Anti-Filamentous Hemagglutinin Antibody Concentrations at BaselineTime frame: Day 0 (baseline)
  3. Geometric Means of Antibody Titers/Concentrations After Primary Series VaccinationTime frame: Day 90 (1 month after third dose)
  4. Number of Participants With Seroprotection After Primary Series VaccinationTime frame: Day 90 (1 month after third dose)
  5. Number of Participants with Vaccine Response or Seroconversion After Primary Series VaccinationTime frame: Day 0 (baseline), Day 90 (1 month after third dose)
  6. Geometric Means of Antibody Titers/Concentrations After Booster VaccinationTime frame: Day 420 (1 month after booster vaccination)
  7. Number of Participants With Seroprotection After Booster VaccinationTime frame: Day 420 (1 month after booster vaccination)
  8. Number of Participants With Vaccine Response or Seroconversion After Booster VaccinationTime frame: Day 0 (baseline), Day 420 (1 month after booster vaccination)
  9. Number of Participants With Booster Response After Booster VaccinationTime frame: Day 390 (pre-booster), Day 420 (1 month after booster dose)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Soweto, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.